Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Deepak Kilari MD

Deepak Kilari MD profile photo picture

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Member of the Cancer Center

View Curriculum Vitae

Publications (101)

  • Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database. (Jang A, Jindal T, Khaki AR, Jiang CY, Alhalabi O, Nguyen CB, Tsung I, Oh E, Epstein I, Bakaloudi DR, Jaime-Casas S, Nizam A, Glover M, Mabey H, Taylor A, Evans S, Shin D, Pywell C, Abuqayas B, Barata PC, Zakharia Y, Basu A, Kilari D, Bilen MA, Emamekhoo H, Milowsky M, Hoimes CJ, Davis N, Shah S, Gupta S, Tripathi A, Grivas P, Bellmunt J, Alva A, Campbell MT, Chen Z, Fu P, Koshkin VS, Brown JR) Clin Genitourin Cancer 2026 Mar;24(2):102501 PMID: 41644316 SCOPUS ID: 2-s2.0-105029288030 02/06/2026    
  • Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. (Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, Park D, Babu S, Ju Y, Liu L, Henry S, Tirucherai GS, DeWall S, Qatanani M, Marantz JL, Gan L) Nat Med 2026 Mar;32(3):992-1001 PMID: 41530380 PMCID: PMC13004668 SCOPUS ID: 2-s2.0-105027566037 01/14/2026       1 Citation
  • Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors. (Awoyinka I, Sheean P, Papanek P, Flynn KE, Bylow K, Kilari D, Gann P, Banerjee A, Stolley M) Contemp Clin Trials 2026 Feb;161:108205 PMID: 41453520 PMCID: PMC12987546 SCOPUS ID: 2-s2.0-105027232337 12/27/2025    
  • Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. (Kilari D, Henderson NC, Yamamoto K, Yao Y, Hwang C, Barata PC, Bilen MA, Graham L, Garje R, Rothstein S, Haider S, Park JJ, Raychaudhuri R, Pilling A, Chin E, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Sokolova A, Ayanambakkam A, Zakharia Y, Schweizer MT, Armstrong AJ, Dorff TB, Reichert ZR, McKay RR) JCO Precis Oncol 2025 Dec;9:e2500590 PMID: 41348987 SCOPUS ID: 2-s2.0-105028828021 12/05/2025       1 Citation
  • CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer. (Sharma K, Wilson DA, Wang Y, Haider S, Bhatlapenumarthi V, Boiarsky D, Cipriaso JM, Yermakov L, Dutta R, Vashisth M, Coleman IM, Bankhead A, Jadhav SK, Neupane B, Taylor BW, Morrissey C, Schweitzer MT, Montgomery RB, Rao S, Nevalainen MT, Nelson AA, Antonarakis ES, Pilié PG, Berchuk JE, Zarrabi KK, Pritchard CC, Kthari A, Chen HZ, George B, Kurzrock R, Ha G, Nelson PS, Auer PL, Banerjee A, Kilari D, De Sarkar N) bioRxiv 2025 Oct 14 PMID: 41278905 PMCID: PMC12633065 11/24/2025    
  • Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. (Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS) Urol Oncol 2026 Jan;44(1):65.e1-65.e11 PMID: 41152111 SCOPUS ID: 2-s2.0-105024203120 10/29/2025    
  • Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. (Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR) Oncologist 2025 Nov 11;30(11) PMID: 41124032 PMCID: PMC12622373 SCOPUS ID: 2-s2.0-105022010503 10/22/2025    
  • Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. (Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O) Oncologist 2025 Nov 11;30(11) PMID: 41056445 PMCID: PMC12605803 SCOPUS ID: 2-s2.0-105021481152 10/07/2025    
  • Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. (McKay RR, Nazari SS, Elliott A, Ribeiro JR, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Smith N, Antonarakis ES, Bagrodia A, Beltran H) Oncologist 2025 Nov 11;30(11) PMID: 41056440 PMCID: PMC12609168 SCOPUS ID: 2-s2.0-105021466827 10/07/2025    
  • Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. (Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS) Cancer Med 2025 Oct;14(19):e71284 PMID: 41031719 PMCID: PMC12486332 SCOPUS ID: 2-s2.0-105017750478 10/01/2025       2 Citations
  • Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. (Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS) Eur Urol 2025 Sep 14 PMID: 40954009 SCOPUS ID: 2-s2.0-105018024297 09/16/2025       7 Citations
  • REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens. (Zhong J, Jang A, Abuqayas B, Basu A, Benjamin DJ, Bhatlapenumarthi V, Bilen MA, Buch D, Chang M, Chin E, Darabi S, Dhanikonda N, Ghatalia P, Grigg CM, Grier AL, Jindal T, Jung J, Kilari D, Kumar HLS, Lee S, Neelands B, Pandya C, Pawalek J, Staggers J, Yildirim A, Zakharia Y, Zarrabi KK, Zimmerman M, Sledge G, Spetzler D, Elliott A, McKay RR, Barata PC) Oncologist 2025 Jun 04;30(6) PMID: 40536267 PMCID: PMC12204391 SCOPUS ID: 2-s2.0-105009317413 06/19/2025    
  • Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC). (McKay RR, Nazari SS, Elliott A, Smith N, Barata PC, Kilari D, Rose BS, Garje R, Bagrodia A, Agarwal N, Antonarakis ES, Beltran H) Journal of Clinical Oncology June 2025;43:5050-5050 SCOPUS ID: 2-s2.0-105030522937 06/01/2025       1 Citation
  • 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY) Front Oncol 2025;15:1541878 PMID: 40265030 PMCID: PMC12011585 SCOPUS ID: 2-s2.0-105003426725 04/23/2025       2 Citations
  • YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study. (Basu A, Sidhom F, Hwang C, Ferguson J, Peyton C, Bae S, Kilari D, Desai A, Rais-Bahrami S) J Natl Compr Canc Netw 2025 Mar 28;23(3.5) PMID: 40154405 SCOPUS ID: 2-s2.0-105002494258 03/29/2025       1 Citation
  • 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L) Commun Med (Lond) 2025 Mar 04;5(1):61 PMID: 40038525 PMCID: PMC11880319 SCOPUS ID: 2-s2.0-86000110322 03/05/2025       5 Citations
  • Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. (Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT) Eur Urol Oncol 2026 Apr;9(2):430-437 PMID: 39920014 PMCID: PMC12325686 02/08/2025    
  • Online Portal Use of Pathology Reports in Patients With Solid Tumors. (Bo AY, Cheng YC, George B, Kilari D, Thompson JR, Jorns JM) Arch Pathol Lab Med 2025 Aug 01;149(8):734-740 PMID: 39722594 SCOPUS ID: 2-s2.0-105012641278 12/26/2024       1 Citation
  • Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. (Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS) Eur Urol Oncol 2025 Apr;8(2):258-262 PMID: 39709257 SCOPUS ID: 2-s2.0-105001942130 12/22/2024       7 Citations
  • Non-clear cell renal cell carcinoma narrative review: where we are in 2024. (Pierro MJ, Gallan A, Kilari D) Transl Cancer Res 2024 Nov 30;13(11):6403-6412 PMID: 39697750 PMCID: PMC11651800 SCOPUS ID: 2-s2.0-85211012802 12/19/2024       5 Citations
  • Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D) Clinical Genitourinary Cancer December 2024;22(6) SCOPUS ID: 2-s2.0-85203009546 12/01/2024    
  • Non-clear cell renal cell carcinoma narrative review: where we are in 2024 (Pierro MJ, Gallan A, Kilari D) Translational Cancer Research 30 November 2024;13(11):6403-6412 SCOPUS ID: 2-s2.0-85211012802 11/30/2024       5 Citations
  • 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY) medRxiv 2024 Oct 27 PMID: 39502659 PMCID: PMC11537326 11/06/2024    
  • Editorial: Bladder preservation options for bladder cancer. (Davis NB, Kilari D, Kessler ER, Smelser WW) Front Oncol 2024;14:1493854 PMID: 39391248 PMCID: PMC11464248 SCOPUS ID: 2-s2.0-85206092308 10/11/2024    
  • Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends. (Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D) Cancer Manag Res 2024;16:1267-1283 PMID: 39308935 PMCID: PMC11416116 SCOPUS ID: 2-s2.0-85204934732 09/23/2024       8 Citations
  • Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. (Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators) N Engl J Med 2024 Nov 14;391(19):1773-1786 PMID: 39282910 SCOPUS ID: 2-s2.0-85207709532 09/17/2024       254 Citations
  • Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer. (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D) Clin Genitourin Cancer 2024 Dec;22(6):102187 PMID: 39241311 SCOPUS ID: 2-s2.0-85203009546 09/07/2024    
  • DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. (Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT) JCO Precis Oncol 2024 Aug;8:e2400014 PMID: 39178368 PMCID: PMC11346579 SCOPUS ID: 2-s2.0-85202867052 08/23/2024       7 Citations
  • Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. (Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES) Prostate Cancer Prostatic Dis 2025 Jun;28(2):411-418 PMID: 39134652 SCOPUS ID: 2-s2.0-85201272323 08/13/2024       14 Citations
  • Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. (Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ) Prostate Cancer Prostatic Dis 2025 Jun;28(2):419-426 PMID: 39019980 PMCID: PMC11739431 SCOPUS ID: 2-s2.0-85198824543 07/18/2024       5 Citations
  • Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617. (Panian J, Henderson N, Barata PC, Bilen MA, Graham L, Heath EI, Herchenhorn D, Hwang C, Kilari D, Koshkin VS, Nauseef JT, Sokolova A, Zakharia Y, Schweizer MT, Dorff TB, Armstrong AJ, Alva AS, McKay RR) Journal of Clinical Oncology June 2024;42(16):5050-5050 SCOPUS ID: 2-s2.0-105010372473 06/01/2024       2 Citations
  • Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. (Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ) JCO Precis Oncol 2024 Apr;8:e2300567 PMID: 38579192 PMCID: PMC11018169 SCOPUS ID: 2-s2.0-85198519208 04/05/2024       19 Citations
  • Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. (Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T) Prostate Cancer Prostatic Dis 2025 Jun;28(2):378-384 PMID: 38383885 PMCID: PMC12106060 SCOPUS ID: 2-s2.0-85185439499 02/22/2024       13 Citations
  • New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma. (Aggen DH, Garcia A, Saro Suarez JM, Sauer A, Cristiani S, Brophy FE, Streets S, Norry E, Nelson AA, Kilari D, Garmezy B, Charlson JA, Zugazagoitia J, Calvo E, Moreno I, Moreno V, Hoimes CJ, Hong DS, Cervantes A) Journal of Clinical Oncology February 2024;42:TPS708-TPS708 SCOPUS ID: 2-s2.0-105024695982 02/01/2024       5 Citations
  • Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. (Nizam A, Jindal T, Jiang CY, Alhalabi O, Bakaloudi DR, Talukder R, Davidsohn MP, Nguyen CB, Oh E, Taylor AK, Lemke E, Kilari D, Hoimes CJ, Emamekhoo H, Gupta S, Bellmunt J, Grivas P, Campbell MT, Alva AS, Koshkin VS) Journal of Clinical Oncology February 2024;42:537-537 SCOPUS ID: 2-s2.0-105024720324 02/01/2024       15 Citations
  • PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). (Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group) J Clin Oncol 2024 Apr 01;42(10):1114-1123 PMID: 38261983 PMCID: PMC11637124 SCOPUS ID: 2-s2.0-85186714362 01/23/2024       36 Citations
  • Editorial: Bladder preservation options for bladder cancer (Davis NB, Kilari D, Kessler ER, Smelser WW) Frontiers in Oncology 2024;14 SCOPUS ID: 2-s2.0-85206092308 01/01/2024    
  • Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC) (McKay RR, Nazari S, Elliott A, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Nabhan C, Beltran H, Antonarakis ES, Bagrodia A) Journal of Clinical Oncology 2024;42(16) SCOPUS ID: 2-s2.0-105023398527 01/01/2024    
  • Preliminary analysis of baseline characteristics, patient reported outcomes (PROs), and treatment selection in ODYSSEY (Harrison MR, Bhavsar NA, Ged Y, Alva AS, Zakharia Y, Wong RL, Costello BA, Maughan BL, Kilari D, Jabusch S, Ward KT, Wulff-Burchfield EM, Zhang T, Page C, Troy JD, Scales CD, George DJ) Journal of Clinical Oncology 2024;42(4) SCOPUS ID: 2-s2.0-105023386571 01/01/2024    
  • The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium (Yamamoto KL, Henderson N, Hwang C, Barata PC, Bilen MA, Kilari D, Graham L, Garje R, Rothstein S, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Schweizer MT, Armstrong AJ, Dorff TB, Alva AS, McKay RR) Journal of Clinical Oncology 2024;42(4) SCOPUS ID: 2-s2.0-105010383651 01/01/2024    
  • Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study (Jindal T, Alhalabi O, Nguyen CB, Bakaloudi DR, Nizam A, Bilen MA, Basu A, Zakharia Y, Milowsky MI, Brown JR, Kilari D, Shah S, Emamekhoo H, Grivas P, Hoimes CJ, Gupta S, Bellmunt J, Campbell MT, Alva AS, Koshkin VS) Journal of Clinical Oncology 2024;42(4) SCOPUS ID: 2-s2.0-105010525092 01/01/2024    
  • Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. (Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Nizam A, Basu A, Bilen MA, Zakharia Y, Milowsky MI, Brown JR, Kilari D, Emamekhoo H, Hoimes CJ, Khaki AR, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS) Journal of Clinical Oncology 2024;42(4):652-652 SCOPUS ID: 2-s2.0-105010401046 01/01/2024       11 Citations
  • Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database (Jiang CY, Hwang H, Jindal T, Qiao W, Epstein I, Nguyen CB, Gupta S, Shah S, Bilen MA, Milowsky MI, Hoimes CJ, Kilari D, Zakharia Y, Emamekhoo H, Grivas P, Bellmunt J, Alva AS, Koshkin VS, Campbell MT, Alhalabi O) Journal of Clinical Oncology 2024;42(4) SCOPUS ID: 2-s2.0-105010399734 01/01/2024       3 Citations
  • A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC). (Kilari D, Kadambi SG, Baran AM, Zittel J, Burfeind JD, Messing EM, Van Veldhuizen PJ, Bylow KA, Sahasrabudhe DM, Mohile SG, Fung C) Journal of Clinical Oncology 2024;42(16_suppl):5089-5089 SCOPUS ID: 2-s2.0-105024233170 01/01/2024    
  • Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB). (Bhatlapenumarthi V, De Sarkar N, Patwari A, Antonarakis ES, Nelson AA, Kilari D) Journal of Clinical Oncology 2024;42(4):206-206 SCOPUS ID: 2-s2.0-105024484473 01/01/2024       1 Citation
  • Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part. (Vaishampayan UN, Sweis RF, Kilari D, Tarhini AA, Gainor JF, Barve MA, Sonpavde GP, McKean M, Park DJ, Babu S, Ju Y, Liu L, Henry S, Gan L, Yap TA) Journal of Clinical Oncology 2024;42(16):2507-2507 SCOPUS ID: 2-s2.0-105024435535 01/01/2024       3 Citations
  • Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study. (Nizam A, Jindal T, Jiang CY, Alhalabi O, Davidsohn MP, Bakaloudi DR, Talukder R, Nguyen CB, Oh E, Taylor AK, Bilen MA, Basu A, Kilari D, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS) Journal of Clinical Oncology 2024;42(4_suppl):667-667 SCOPUS ID: 2-s2.0-105010383252 01/01/2024       5 Citations
  • Novel targets in development for advanced renal cell carcinoma (Thapa B, Nelson A, Kilari D) Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma 1 November 2023:309-342 SCOPUS ID: 2-s2.0-85198394501 11/01/2023       1 Citation
  • 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies. (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L) medRxiv 2024 Oct 17 PMID: 37904926 PMCID: PMC10615016 10/31/2023    
  • Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. (Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC) JAMA Netw Open 2023 Sep 05;6(9):e2334208 PMID: 37721753 PMCID: PMC10507489 SCOPUS ID: 2-s2.0-85171513698 09/18/2023       11 Citations
  • Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. (Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A) Res Sq 2023 Aug 10 PMID: 37609284 PMCID: PMC10441451 08/23/2023    
  • Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. (Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekhoo H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D'Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH) Clin Genitourin Cancer 2023 Dec;21(6):694-702 PMID: 37558529 SCOPUS ID: 2-s2.0-85167777292 08/10/2023       2 Citations
  • Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. (Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR) Oncologist 2024 Oct 03;29(10):870-877 PMID: 37368355 PMCID: PMC11448883 SCOPUS ID: 2-s2.0-85205741132 06/27/2023       10 Citations
  • The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction. (Pierro MJ, Kilari D) Eur Urol Focus 2023 May;9(3):409-410 PMID: 37005166 SCOPUS ID: 2-s2.0-85151400919 04/03/2023       1 Citation
  • Comprehensive genomic profiling: Does timing matter? (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B) Front Oncol 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 SCOPUS ID: 2-s2.0-85149381128 03/04/2023       8 Citations
  • Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. (Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y) J Immunother Cancer 2023 Feb;11(2) PMID: 36822667 PMCID: PMC9950974 SCOPUS ID: 2-s2.0-85148679955 02/24/2023       25 Citations
  • Comprehensive genomic profiling: Does timing matter? (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B) Frontiers in Oncology 2023;13 SCOPUS ID: 2-s2.0-85149381128 01/01/2023       8 Citations
  • Management of Acute Liver Dysfunction Due to Budd-Chiari Syndrome in the Setting of Tumor Thrombus and Advanced Renal Cell Carcinoma. (Stevens-Haas C, Maniar V, Dietrich P, Langenstroer P, Joyce L, White S, Kilari D, Hong J, Johnson S) Urology 2023 Mar;173:32-33 PMID: 36535364 SCOPUS ID: 2-s2.0-85146041736 12/20/2022    
  • Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. (Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR) Clin Genitourin Cancer 2023 Feb;21(1):55-62 PMID: 36411184 SCOPUS ID: 2-s2.0-85142487844 11/22/2022       3 Citations
  • Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. (Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, Kilari D, Park J, Huang CC, Kohli M, Wang L) Cancers (Basel) 2022 Sep 28;14(19) PMID: 36230636 PMCID: PMC9562906 SCOPUS ID: 2-s2.0-85139907579 10/15/2022       5 Citations
  • Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. (Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV) Oncologist 2022 Oct 01;27(10):e783-e795 PMID: 36124924 PMCID: PMC9526483 SCOPUS ID: 2-s2.0-85139536391 09/21/2022       17 Citations
  • Bystander LECT2 amyloidosis in tumor nephrectomy. (Gallan AJ, Bhasin-Chhabra B, Kilari D, Johnson S, D'Souza A) CEN Case Rep 2023 Feb;12(1):104-109 PMID: 35986199 PMCID: PMC9892383 SCOPUS ID: 2-s2.0-85147317519 08/20/2022       1 Citation
  • Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators) N Engl J Med 2022 Mar 24;386(12):1132-1142 PMID: 35179323 PMCID: PMC9844551 SCOPUS ID: 2-s2.0-85127335942 02/19/2022       818 Citations
  • Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. (Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS) Cancer 2022 Mar 15;128(6):1194-1205 PMID: 34882781 SCOPUS ID: 2-s2.0-85120821529 12/10/2021       78 Citations
  • Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? (Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT) Cancers (Basel) 2021 Oct 17;13(20) PMID: 34680353 PMCID: PMC8533841 SCOPUS ID: 2-s2.0-85117018634 10/24/2021       22 Citations
  • PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. (Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R) Prostate Cancer Prostatic Dis 2022 Sep;25(3):388-396 PMID: 34363009 PMCID: PMC9385488 SCOPUS ID: 2-s2.0-85112618674 08/08/2021       26 Citations
  • Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. (Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF) Pract Radiat Oncol 2021;11(6):527-533 PMID: 33848618 PMCID: PMC8638529 SCOPUS ID: 2-s2.0-85107984420 04/14/2021       5 Citations
  • Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. (Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA) Front Oncol 2020;10:581189 PMID: 33194712 PMCID: PMC7642690 SCOPUS ID: 2-s2.0-85095695510 11/17/2020       14 Citations
  • Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort (Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA) Frontiers in Oncology 22 October 2020;10 SCOPUS ID: 2-s2.0-85095695510 10/22/2020       14 Citations
  • Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. (Pierro M, Raychaudhuri R, Lea WB, Rilling W, Davis N, Bylow K, Kilari D) Clin Genitourin Cancer 2021 Feb;19(1):87-91 PMID: 32778506 SCOPUS ID: 2-s2.0-85089247313 08/12/2020       1 Citation
  • CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. (Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A) JCO Precis Oncol 2020;4:382-392 PMID: 32671317 PMCID: PMC7363399 07/17/2020    
  • Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. (Kmak JA, Agarwal N, He Y, Heilmann AM, Miller VA, Ross JS, Pal SK, Ali SM, Kilari D) Case Rep Oncol 2020;13(1):456-461 PMID: 32399016 PMCID: PMC7204854 SCOPUS ID: 2-s2.0-85084410749 05/14/2020       3 Citations
  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. (Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M) Prostate Cancer Prostatic Dis 2020 Dec;23(4):705-713 PMID: 32203070 PMCID: PMC7501185 SCOPUS ID: 2-s2.0-85082799475 03/24/2020       21 Citations
  • Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. (George G, Schmidt L, Tolat P, Riese M, Kilari D) J Immunother Cancer 2020 Feb;8(1) PMID: 32114501 PMCID: PMC7057424 SCOPUS ID: 2-s2.0-85080840435 03/03/2020       4 Citations
  • The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? (Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D) Clin Genitourin Cancer 2020 Aug;18(4):e478-e483 PMID: 32085986 SCOPUS ID: 2-s2.0-85079745146 02/23/2020       5 Citations
  • Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. (Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT) Mol Cancer Ther 2020 Jan;19(1):231-246 PMID: 31548294 PMCID: PMC6946850 SCOPUS ID: 2-s2.0-85077669370 09/25/2019       21 Citations
  • Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. (Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA) J Natl Compr Canc Netw 2019 Jul 01;17(7):829-837 PMID: 31319388 SCOPUS ID: 2-s2.0-85070084884 07/19/2019       14 Citations
  • Palliative care education for oncologists: how are we doing? (Robbins JR, Kilari D, Johnston F) Ann Palliat Med 2019 Sep;8(4):364-371 PMID: 30943741 SCOPUS ID: 2-s2.0-85073085975 04/05/2019       9 Citations
  • Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. (Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P) Biol Blood Marrow Transplant 2019 Jun;25(6):1099-1106 PMID: 30794931 PMCID: PMC6559839 SCOPUS ID: 2-s2.0-85064954131 02/23/2019       13 Citations
  • CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade (Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A) JCO Precision Oncology 2019;3:382-392 SCOPUS ID: 2-s2.0-85086473721 01/01/2019       80 Citations
  • Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. (Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L) Prostate Cancer Prostatic Dis 2018 Sep;21(3):411-418 PMID: 29858592 PMCID: PMC6126974 SCOPUS ID: 2-s2.0-85047928806 06/03/2018       36 Citations
  • Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. (Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S) Case Rep Oncol 2017;10(3):897-909 PMID: 29279690 PMCID: PMC5731100 SCOPUS ID: 2-s2.0-85031826225 12/28/2017       54 Citations
  • Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. (Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L) Oncotarget 2017 Sep 08;8(38):63703-63714 PMID: 28969022 PMCID: PMC5609954 SCOPUS ID: 2-s2.0-85028376284 10/04/2017       59 Citations
  • Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. (Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D) Clin Genitourin Cancer 2017 Oct;15(5):e897-e901 PMID: 28645484 SCOPUS ID: 2-s2.0-85020921698 06/25/2017       15 Citations
  • Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. (Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT) Oncotarget 2017 Jan 10;8(2):3724-3745 PMID: 27741508 PMCID: PMC5356914 SCOPUS ID: 2-s2.0-85009775057 10/16/2016       112 Citations
  • Applications of Extracellular RNAs in Oncology. (Thompson JR, Zhu J, Kilari D, Wang L) Mol Diagn Ther 2017 Feb;21(1):1-11 PMID: 27688207 SCOPUS ID: 2-s2.0-84989170631 10/01/2016       2 Citations
  • Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. (Flynn T, Guancial EA, Kilari M, Kilari D) Clin Genitourin Cancer 2017 Feb;15(1):e95-e97 PMID: 27641657 SCOPUS ID: 2-s2.0-84994708562 09/20/2016       11 Citations
  • Gaps in nutritional research among older adults with cancer. (Presley CJ, Dotan E, Soto-Perez-de-Celis E, Jatoi A, Mohile SG, Won E, Alibhai S, Kilari D, Harrison R, Klepin HD, Wildes TM, Mustian K, Demark-Wahnefried W) J Geriatr Oncol 2016 Jul;7(4):281-92 PMID: 27197919 PMCID: PMC4969118 SCOPUS ID: 2-s2.0-84971324913 05/21/2016       56 Citations
  • Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. (Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM) J Geriatr Oncol 2016 Jul;7(4):293-304 PMID: 27197916 PMCID: PMC4969104 SCOPUS ID: 2-s2.0-84971268860 05/21/2016       63 Citations
  • Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES) PLoS One 2016;11(5):e0155503 PMID: 27187160 PMCID: PMC4871463 SCOPUS ID: 2-s2.0-84969505076 05/18/2016       7 Citations
  • Role of copper transporters in platinum resistance. (Kilari D, Guancial E, Kim ES) World J Clin Oncol 2016 Feb 10;7(1):106-13 PMID: 26862494 PMCID: PMC4734932 SCOPUS ID: 2-s2.0-84956653652 02/11/2016       110 Citations
  • Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. (Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES) Anticancer Res 2016 Feb;36(2):495-501 PMID: 26851002 SCOPUS ID: 2-s2.0-84962195660 02/07/2016       49 Citations
  • Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. (Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L) Oncotarget 2015 Jun 30;6(18):16411-21 PMID: 25915538 PMCID: PMC4599278 SCOPUS ID: 2-s2.0-84937898954 04/29/2015       42 Citations
  • How we treat early systemic prostate cancer in older men. (Kilari D, Dale W, Mohile SG) J Geriatr Oncol 2014 Oct 01;5(4):337-42 PMID: 25248671 SCOPUS ID: 2-s2.0-84908256130 09/25/2014       9 Citations
  • Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. (Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH) Lung Cancer 2014 Jul;85(1):88-93 PMID: 24792335 PMCID: PMC4090351 SCOPUS ID: 2-s2.0-84901624214 05/06/2014       83 Citations
  • Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. (Kilari D, Venci N, Friedberg J, Bennett JM) Leuk Res Rep 2013;2(1):4-6 PMID: 24371766 PMCID: PMC3850386 SCOPUS ID: 2-s2.0-84878370734 12/29/2013       7 Citations
  • An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. (Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M) J Mens Health 2012 Sep 01;9(3):182-189 PMID: 24416090 PMCID: PMC3886726 SCOPUS ID: 2-s2.0-84865162164 09/01/2012       1 Citation
  • An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer (Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M) Journal of Men S Health September 2012;9(3):182-189 SCOPUS ID: 2-s2.0-84865162164 09/01/2012       1 Citation
  • Management of cancer in the older adult. (Kilari D, Mohile SG) Clin Geriatr Med 2012 Feb;28(1):33-49 PMID: 22326034 SCOPUS ID: 2-s2.0-84856802493 02/14/2012       14 Citations
  • Inpatient management of sickle cell pain: a 'snapshot' of current practice. (Miller ST, Kim HY, Weiner D, Wager CG, Gallagher D, Styles L, Dampier CD, Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN)) Am J Hematol 2012 Mar;87(3):333-6 PMID: 22231150 PMCID: PMC5047515 SCOPUS ID: 2-s2.0-84862777383 01/11/2012       37 Citations
  • Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. (Peters-Lawrence MH, Bell MC, Hsu LL, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith WR, Dampier CD, Minniti CP, Sickle Cell Disease Clinical Research Network (SCDCRN)) Contemp Clin Trials 2012 Mar;33(2):291-7 PMID: 22155024 PMCID: PMC3577351 SCOPUS ID: 2-s2.0-84856218422 12/14/2011       61 Citations
    • Last update: 04/23/2026